- Ring size changes in the development of class I HDAC inhibitors
-
Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.
- Cho, Er-Chieh,Liu, Chi-Yuan,Tang, Di-Wei,Lee, Hsueh-Yun
-
p. 1387 - 1401
(2021/07/06)
-
- Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study
-
Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.
- La, Minh Thanh,Jeong, Byung-Hoon,Kim, Hee-Kwon
-
p. 740 - 743
(2021/03/16)
-
- HDAC DEGRADER
-
The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may
- -
-
-
- Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof
-
The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode
- -
-
-
- Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study
-
Previously, we reported the discovery of a series of N-hydroxycinnamamide-based HDAC inhibitors, among which compound 11y exhibited high HDAC1/3 selectivity. In this current study, structural derivatization of 11y led to a new series of benzamide based HDAC inhibitors. Most of the compounds exhibited high HDACs inhibitory potency. Compound 11a (with 4-methoxybenzoyl as N-substituent in the cap and 4-(aminomethyl) benzoyl as the linker group) exhibited selectivity against HDAC1 to some extent, and showed potent antiproliferative activity against several tumor cell lines. In?vivo studies revealed that compound 11a displayed potent oral antitumor activity in both hematological tumor cell U937 xenograft model and solid tumor cell HCT116 xenograft model with no obvious toxicity. Further modification of benzamide 3, 11a and 19 afforded new thienyl and phenyl compounds (50a, 50b, 63a, 63b and 63c) with dramatic HDAC1 and HDAC2 dual selectivity, and the fluorine containing compound 56, with moderate HDAC3 selectivity.
- Li, Xiaoyang,Zhang, Yingjie,Jiang, Yuqi,Wu, Jingde,Inks, Elizabeth S.,Chou, C. James,Gao, Shuai,Hou, Jinning,Ding, Qinge,Li, Jingyao,Wang, Xue,Huang, Yongxue,Xu, Wenfang
-
p. 185 - 206
(2017/04/21)
-
- Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups
-
As a hot topic of epigenetic studies, histone deacetylases (HDACs) are related to lots of diseases, especially cancer. Further researches indicated that different HDAC isoforms played various roles in a wide range of tumor types. Herein a novel series of HDAC inhibitors with isatin-based caps and o-phenylenediamine-based zinc binding groups have been designed and synthesized through scaffold hopping strategy. Among these compounds, the most potent compound 9n exhibited similar if not better HDAC inhibition and antiproliferative activities against multiple tumor cell lines compared with the positive control entinostat (MS-275). Additionally, compared with MS-275 (IC50 values for HDAC1, 2 and 3 were 0.163, 0.396 and 0.605?μM, respectively), compound 9n with IC50 values of 0.032, 0.256 and 0.311?μM for HDAC1, 2 and 3 respectively, showed a moderate HDAC1 selectivity.
- Gao, Shuai,Zang, Jie,Gao, Qianwen,Liang, Xuewu,Ding, Qinge,Li, Xiaoyang,Xu, Wenfang,Chou, C. James,Zhang, Yingjie
-
p. 2981 - 2994
(2017/05/25)
-
- Inhibitors of histone deacetylase
-
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
- -
-
-
- Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
-
Histone deacetylase (HDAC) inhibition has recently emerged as a novel therapeutic approach for the treatment of various pathological conditions including cancer. Currently, two HDAC inhibitors (HDACi) - Vorinostat and Romidepsin - have been approved for t
- Sodji, Quaovi H.,Kornacki, James R.,McDonald, John F.,Mrksich, Milan,Oyelere, Adegboyega K.
-
p. 340 - 359
(2015/04/27)
-
- Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor
-
The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and
- Methot, Joey L.,Hoffman, Dawn Mampreian,Witter, David J.,Stanton, Matthew G.,Harrington, Paul,Hamblett, Christopher,Siliphaivanh, Phieng,Wilson, Kevin,Hubbs, Jed,Heidebrecht, Richard,Kral, Astrid M.,Ozerova, Nicole,Fleming, Judith C.,Wang, Hongmei,Szewczak, Alexander A.,Middleton, Richard E.,Hughes, Bethany,Cruz, Jonathan C.,Haines, Brian B.,Chenard, Melissa,Kenific, Candia M.,Harsch, Andreas,Secrist, J. Paul,Miller, Thomas A.
-
p. 340 - 345
(2014/05/06)
-
- PHOTOSWITCHABLE HDAC INHIBITORS
-
This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of HDAC having photoswitchable modulators of protein function with short thermal relaxation kinetics. The compounds
- -
-
-
- INHIBITORS OF HISTONE DEACETYLASE
-
ABSTRACT OF THE DISCLOSURE This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
- -
-
Page/Page column 88; 89
(2009/06/27)
-
- Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
-
A class of biaryl benzamides was identified and optimized as selective HDAC1&2 inhibitors (SHI-1:2). These agents exhibit selectivity over class II HDACs 4-7, as well as class I HDACs 3 and 8; providing examples of selective HDAC inhibitors for the HDAC i
- Witter, David J.,Harrington, Paul,Wilson, Kevin J.,Chenard, Melissa,Fleming, Judith C.,Haines, Brian,Kral, Astrid M.,Secrist, J. Paul,Miller, Thomas A.
-
p. 726 - 731
(2008/12/23)
-
- BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE
-
The invention relates to the inhibition of histone deacetylase. The invention provides compounds which are derivatives of benzamide and suitable in methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions .
- -
-
Page/Page column 83
(2008/06/13)
-
- Spirocyclic compounds
-
The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of n
- -
-
Page/Page column 28-29
(2008/06/13)
-
- ARYL-FUSED SPIROCYCLIC COMPOUNDS
-
The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of ne
- -
-
Page/Page column 51
(2008/06/13)
-
- INHIBITORS OF HISTONE DEACETYLASE
-
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
- -
-
Page/Page column 203-204
(2010/02/11)
-
- Glutamate receptor antagonists
-
The present invention is a compound of formula wherein X is an ethynediyl group, R1, R2and R3are as defined in the specification.
- -
-
-